scholarly journals Intraoperative enrichment of bone autograft with autologous bone marrow-derived mononuclear cells isolated simultaneously: moving towards tissue engineering in situ

2020 ◽  
Author(s):  
D.S. Baranovskii ◽  
B.G. Akhmedov ◽  
O.A. Krasilnikova ◽  
A.G. Demchenko ◽  
M.E. Krasheninnikov ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Tissue ◽  
Metabolic Activity ◽  
Mononuclear Cells ◽  
P Value ◽  
Active Growth ◽  
Simple Method ◽  
Bone Fragments ◽  
Autologous Bone ◽  
Bone Autograft

AbstractBackgroundThe use of tissue-engineered bone autografts is a promising approach for bone defects restoration. The isolation of cells and their seeding on bone autograft is usually carried out in a laboratory, requiring significant time and two separate surgical interventions. Intraoperative creation of tissue-engineered bone autograft can represent a perspective solution. The aim of this study is to investigate the possibility of creation of tissue-engineered bone autograft by intraoperative enrichment of bone tissue with bone marrow-derived mononuclear cells (BM-MNCs) isolated simultaneously.MethodsRed bone marrow and autologous bone tissue (bone fragments and bone chips) of the donor were harvested intraoperatively. BM-MNCs were isolated, and bone fragments were enriched with BM-MNCs intraoperatively. Assessment of the adhesion and proliferation of BM-MNCs on bone fragments was carried out by fluorescence microscopy and histological examination. MTT assay was used to compare metabolic activity of BM-MNCs and wBMA cells seeded on bone chips.ResultsAutologous bone fragments were colonized with autologous BM-MNCs isolated simultaneously in the O.R. with further adhesion and active growth of cells. When seeded on bone chips, metabolic activity of BM-MNCs was statistically significantly higher compared to wBMA cells (p-value=0.0272) on day 14. There was no difference in metabolic activity of BM-MNCs and wBMA cells cultured in nutrient medium without bone chips.ConclusionTechnically simple method of intraoperative enrichment of autologous bone fragments with BM-MNCs isolated simultaneously allowed to create tissue-engineered bone autograft in the O.R. The safety and effectiveness of intraoperatively enriched autografts should be investigated further.

scholarly journals Corrigendum to “Characterization of Bone Marrow Mononuclear Cells on Biomaterials for Bone Tissue EngineeringIn Vitro”

2015 ◽  
Vol 2015 ◽  
pp. 1-1
Author(s):  
Dirk Henrich ◽  
René Verboket ◽  
Alexander Schaible ◽  
Kerstin Kontradowitz ◽  
Elsie Oppermann ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Tissue ◽  
Mononuclear Cells ◽  
Bone Marrow Mononuclear Cells

scholarly journals Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

Blood ◽  
1992 ◽  
Vol 80 (7) ◽  
pp. 1666-1672
Author(s):  
S Jagannath ◽  
DH Vesole ◽  
L Glenn ◽  
J Crowley ◽  
B Barlogie
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Mononuclear Cells ◽  
Intensive Therapy ◽  
Autologous Bone Marrow ◽  
Blood Stem Cell ◽  
High Dose ◽  
Platelet Recovery ◽  
Gm Csf ◽  
Autologous Bone

To improve the safety of autotransplantation for myeloma, peripheral blood stem cell (PBSC) collection was attempted in 75 previously treated patients after the administration of high-dose cyclophosphamide (HD-CTX; 6 g/m2) with or without granulocyte-macrophage colony- stimulating factor (GM-CSF). Sixty patients subsequently received melphalan 200 mg/m2 (57 patients) or melphalan 140 mg/m2 and total body irradiation (850 cGy) (3 patients) supported by both autologous bone marrow and PBSC; 38 patients received GM-CSF posttransplantation. Among 72 patients undergoing PBSC apheresis, “good” mobilization (greater than 50 colony-forming units granulocyte-macrophage [CFU-GM] per 10(5) mononuclear cells) was achieved when prior chemotherapy did not exceed 1 year and when GM-CSF was used post-HD-CTX; similarly, rapid platelet recovery to 50,000/microL within 2 weeks was associated with “good” PBSC mobilization. These same variables also predicted for rapid engraftment after autotransplantation, so that hematologic recovery (granulocytes greater than 500/microL and platelets greater than 50,000/microL) proceeded within 2 weeks among the 37 patients with “good” PBSC collection. As a result of rapid neutrophil recovery (greater than 500/microL) within a median of 2 weeks, infectious complications both post-HD-CTX and posttransplant were readily manageable, resulting in only one treatment-related death post-HD-CTX. The cumulative response rate (greater than or equal to 75% cytoreduction) for all 75 patients was 68%, with 12-month event-free and overall survival projections of about 85%. Using both bone marrow and PBSC together with GM-CSF, autotransplants are safe and appear effective in myeloma, especially when prior therapy had been limited to less than 1 year. More than 80% of transplanted patients achieved complete hematologic recovery within a median of 1 month posttransplant (granulocytes greater than 1,500/microL; platelets greater than 100,000/microL; hemoglobin greater than 10 g%), thus providing sufficient hematopoietic reserve for further chemotherapy in the event of posttransplant relapse.

scholarly journals Infusion of freshly isolated autologous bone marrow derived mononuclear cells prevents endotoxin-induced lung injury in an ex-vivo perfused swine model

2013 ◽  
Vol 4 (2) ◽  
pp. 26 ◽  
Author(s):  
Mauricio Rojas ◽  
Richard E Parker ◽  
Natalie Thorn ◽  
Claudia Corredor ◽  
Smita S Iyer ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Lung Injury ◽  
Mononuclear Cells ◽  
Ex Vivo ◽  
Autologous Bone Marrow ◽  
Swine Model ◽  
Autologous Bone
Sign in / Sign up

Export Citation Format

Share Document